[en] Objectives: There is emerging evidence supporting sequential therapy with an osteoanabolic followed by an antiresorptive in patients at high-risk of fragility fractures. This study assessed the cost-effectiveness of sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) [(ABL/ALN)] compared with teriparatide (TPTD) followed by ALN (TPTD/ALN).
Methods: A previously validated Markov microsimulation model was adapted to estimate the cost-effectiveness of sequential ABL/ALN compared with sequential TPTD/ALN and no treatment with a lifetime horizon from the US payer perspective. Patients were assumed to receive ABL or TPTD for 18 months followed by 5 years of ALN in line with clinical recommendations. The effects of ABL on fracture risk were derived from the ACTIVExtend trial. The effects of TPTD were assumed to be maintained during subsequent ALN treatment, consistent with ACTIVExtend findings for ABL. Evaluation was completed for patients, aged 50 80 years with a BMD T-score ¡3.5 or with a T-score between ¡2.5 and ¡3.5 and a history of one osteoporotic fracture.
Results: In all simulated populations, sequential ABL/ALN therapy was dominant (lower costs, D14X X higher QALYs) compared with sequential TPTD/ALN therapy, resulting from the improved efficacy and lower drug price of ABL. Probabilistic sensitivity analyses suggested that ABL/ALN was dominant in at least 99% of the simulations. Compared to no treatment, the cost per QALY gained of ABL/ALN D15X X was always below $130,000.
Conclusions: Sequential ABL/ALN therapy is a D16X X cost-effective (dominant) strategy compared with sequential TPTD/ALN therapy for the treatment of US women at increased risk of fractures.
Disciplines :
General & internal medicine
Author, co-author :
Hilisgmann, Mickael
Williams, Setareh A.
Fitzpatrick, Lorraine A.
Silverman, Stuart S.
Weiss, Richard
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture.
Svedbom, A., Hernlund, E., Ivergard, M., Osteoporosis in the European union: a compendium of country-specific reports (2013) Arch Osteoporos, 8, p. 137
Burge, R., Dawson-Hughes, B., Solomon, D.H., Wong, J.B., King, A., Tosteson, A., Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025 (2007) J Bone Miner Res, 22 (3), pp. 465-475
Wright, N.C., Looker, A.C., Saag, K.G., The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine (2014) J Bone Miner Res, 29 (11), pp. 2520-2526
Haentjens, P., Magaziner, J., Colon-Emeric, C.S., Meta-analysis: excess mortality after hip fracture among older women and men (2010) Ann Intern Med, 152 (6), pp. 380-390
Lips, P., van Schoor, N.M., Quality of life in patients with osteoporosis (2005) Osteoporos Int, 16 (5), pp. 447-455
Kanis, J.A., Johnell, O., De Laet, C., A meta-analysis of previous fracture and subsequent fracture risk (2004) Bone, 35 (2), pp. 375-382
Klotzbuecher, C.M., Ross, P.D., Landsman, P.B., Abbott, T.A., 3rd, Berger, M., Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis (2000) J Bone Miner Res, 15 (4), pp. 721-739
Leader, D., Williams, S.A., Curtis, J.R., Osteoporosis-related fracture events in the US (2017) J Manag Care Pharm, 23 (10a), p. S78
Jha, S., Wang, Z., Laucis, N., Bhattacharyya, T., Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis (2015) J Bone Miner Res, 30 (12), pp. 2179-2187
Cramer, J.A., Amonkar, M.M., Hebborn, A., Altman, R., Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis (2005) Curr Med Res Opin, 21 (9), pp. 1453-1460
Imel, E.A., Eckert, G., Modi, A., A proportion of osteoporotic women remains at risk for fractures despite adherence to oral bisphosphonates (2016) Bone, Feb
83, pp. 267-275
Cheng, L.I., Durden, E., Limone, B., Persistance and compliance with osteoporosis therapies among women in a commercially insured population in the United States (2015) J Manag Care Spec Pharm, 21 (9), p. 824. , U322
Silverman, S.L., Siris, E., Kendler, D.L., Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study (2015) Osteoporos Int, 26 (1), pp. 361-372
Tsourdi, E., Langdahl, B., Cohen-Solal, M., Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS (2017) Bone, 105, pp. 11-17
Modi, A., Siris, E.S., Tang, J., Sen, S., Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy (2015) Curr Med Res Opin, 31 (4), pp. 757-765
Miller, P.D., Hattersley, G., Riis, B.J., Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial (2016) JAMA, 316 (7), pp. 722-733
Bone, H.G., Cosman, F., Miller, P.D., ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis (2018) J Clin Endocrinol Metab, 103 (8), pp. 2949-2957
Sculpher, M., ISPOR's initiative on US value assessment frameworks: seeking a role for health economics (2018) Value Health, 21 (2), pp. 171-172
Hiligsmann, M., Gathon, H.J., Bruyere, O., Ethgen, O., Rabenda, V., Reginster, J.Y., Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence (2010) Value Health, 13 (4), pp. 394-401
Hiligsmann, M., Reginster, J.Y., Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium (2011) Pharmacoeconomics, 29 (10), pp. 895-911
Hiligsmann, M., Ethgen, O., Bruyere, O., Richy, F., Gathon, H.J., Reginster, J.Y., Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis (2009) Value Health, 12 (5), pp. 687-696
Camacho, P.M., Petak, S.M., Binkley, N., American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016–executive summary (2016) Endocr Pract, 22 (9), pp. 1111-1118
Sanders, G.D., Neumann, P.J., Basu, A., Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine (2016) JAMA, 316 (10), pp. 1093-1103
http://www.amcp.org/FormatV4/, Academy of Managed Care Pharmacy. The AMCP format for formulary submissions version 4.0. A format for submission of clinical and economic evidence in support of formulary consideration. 2016. Available at: [Accessed November 2017]
Hiligsmann, M., Reginster, J.Y., Tosteson, A.N.A., Bukata, S.V., Saag, K.G., Gold, D.T., Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO) and the US branch of the international osteoporosis foundation (2019) Osteoporos Int., Jan
30 (1), pp. 45-57
Husereau, D., Drummond, M., Petrou, S., Consolidated health economic evaluation reporting standards (CHEERS) statement (2013) Value Health, 16 (2), pp. e1-e5
Ettinger, B., Black, D.M., Dawson-Hughes, B., Pressman, A.R., Melton, L.J., 3rd, Updated fracture incidence rates for the US version of FRAX (2010) Osteoporos Int, 21 (1), pp. 25-33
Kanis, J.A., Johnell, O., Oden, A., Jonsson, B., De Laet, C., Dawson, A., Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis (2000) Bone, 27 (5), pp. 585-590
Johansson, H., Siggeirsdottir, K., Harvey, N.C., Imminent risk of fracture after fracture (2017) Osteoporos Int, 28 (3), pp. 775-780
United States life table (2014), https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_04.pdf, 2014. Available from: [Accessed November 2017]
Tran, T., Bliuc, D., van Geel, T., Population-wide impact of non-hip non-vertebral fractures on mortality (2017) J Bone Miner Res, 32 (9), pp. 1802-1810
Kanis, J.A., Oden, A., Johnell, O., De Laet, C., Jonsson, B., Excess mortality after hospitalisation for vertebral fracture (2004) Osteoporos Int, 15 (2), pp. 108-112
Kanis, J.A., Oden, A., Johnell, O., De Laet, C., Jonsson, B., Oglesby, A.K., The components of excess mortality after hip fracture (2003) Bone, 32 (5), pp. 468-473
Leibson, C.L., Tosteson, A.N.A., Gabriel, S.E., Ransom, J.E., Melton, L.J., Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study (2002) J Am Geriatr Soc, 50 (10), pp. 1644-1650
https://fred.stlouisfed.org/series/CPIMEDSL, U.S. Bureau of Labor Statistics, Consumer price index for all urban consumers: medical care (CPIMEDSL), retrieved from FRED, Federal Reserve Bank of St. Louis
Available from: [Accessed November 2017]
Bonafede, M., Shi, N., Viswanathan, H.N., Yurgin, N., Osteoporosis-related fracture costs among female commercially insured and medicare patients (2011) Value Health, 14 (3), p. A125. , A125-
Tosteson, A.N., Melton, L.J., 3rd, Dawson-Hughes, B., Cost-effective osteoporosis treatment thresholds: the United States perspective (2008) Osteoporos Int, 19 (4), pp. 437-447
Weaver, J., Sajjan, S., Lewiecki, E.M., Harris, S.T., Marvos, P., Prevalence and cost of subsequent fractures among U.S. patients with an incident fracture (2017) J Manag Care Spec Pharm, 23 (4), pp. 461-471
https://www.genworth.com/about-us/industry-expertise/cost-of-care.html, Genworth. Cost of care survey, conducted by CareScout. Long Term Care Costs Across the United States. 2017. Available from: [Accessed November 2017]
Hanmer, J., Lawrence, W.F., Anderson, J.P., Kaplan, R.M., Fryback, D.G., Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores (2006) Med Decis Making, 26 (4), pp. 391-400
Svedbom, A., Borgstom, F., Hernlund, E., Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS (2018) Osteoporos Int, 29 (3), pp. 557-566
Hiligsmann, M., Ethgen, O., Richy, F., Reginster, J.Y., Utility values associated with osteoporotic fracture: a systematic review of the literature (2008) Calcif Tissue Int, 82 (4), pp. 288-292
https://www.nice.org.uk/guidance/ta160, National Institue for Health and Clinical Excellence, United Kingdom. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. Available from: [Accessed November 2017]
Black, D.M., Bilezikian, J.P., Ensrud, K.E., Greenspan, S.L., Palermo, L., Hue, T., One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis (2005) N Engl J Med, 353 (6), pp. 555-565
Hiligsmann, M., Evers, S.M., Ben Sedrine, W., A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis (2015) Pharmacoeconomics, 33 (3), pp. 205-224
Strom, O., Landfeldt, E., Garellick, G., Residual effect after oral bisphosphonate treatment and healthy adherer effects-the Swedish adherence register analysis (SARA) (2015) Osteoporosis Int, 26 (1), pp. 315-325
RED BOOK online. Wholesale acquisition cost. [Accessed December 2017]
The Medicare Learning Network®, MLN Connects®, and MLN Matters®. The ABCs of the annual wellness visit (AWV). G0349 code
Liu, H., Michaud, K., Nayak, S., Karpf, D.B., Owens, D.K., Garber, A.M., The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis (2006) Arch Int Med, 166 (11), pp. 1209-1217
Parthan, A., Kruse, M., Yurgin, N., Huang, J., Viswanathan, H.N., Taylor, D., Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US (2013) Appl Health Econ Health Pol, 11 (5), pp. 485-497
Neumann, P.J., Cohen, J.T., Weinstein, M.C., Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold (2014) N Engl J Med, 371 (9), pp. 796-797
Dubois, R., Cost–effectiveness thresholds in the USA: are they coming? Are they already here? (2016) J Comp Eff Res, 5 (1), pp. 9-11
Neer, R.M., Arnaud, C.D., Zanchetta, J.R., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis (2001) N Engl J Med, 344 (19), pp. 1434-1441
Briggs, A., Claxton, K., Sculpher, M., Decision modeling for health economic evaluation (2006), Oxford University Press
Cosman, F., Nieves, J.W., Dempster, D.W., Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis (2017) J Bone Miner Res, 32 (2), pp. 198-202
Murphy, D.R., Smolen, L.J., Klein, T.M., Klein, R.W., The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden (2012) BMC Musculoskelet Disord, 13, p. 213
Langdahl, B.L., Silverman, S., Fujiwara, S., Saag, K., Napoli, N., Soen, S., Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies (2018) Bone, 116, pp. 58-66
Brauer, C.A., Coca-Perraillon, M., Cutler, D.M., Rosen, A.B., Incidence and mortality of hip fractures in the United States (2009) JAMA, 302 (14), pp. 1573-1579
Silverman, S.L., Minshall, M.E., Shen, W., Harper, K.D., Xie, S., The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the multiple outcomes of raloxifene evaluation study (2001) Arthritis Rheum, 44 (11), pp. 2611-2619
O'Hagan, A., Stevenson, M., Madan, J., Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA (2007) Health Econ, 16 (10), pp. 1009-1023
Kanis, J.A., Johnell, O., Oden, A., Jonsson, B., De Laet, C., Dawson, A., Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis (2000) Bone, 27 (5), pp. 585-590
Marshall, D., Johnell, O., Wedel, H., Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures (1996) Br Med J, 312 (7041), pp. 1254-1259
Johnell, O., Kanis, J.A., Oden, A., Johansson, H., De Laet, C., Delmas, P., Predictive value of BMD for hip and other fractures (2005) J Bone Miner Res, 20 (7), pp. 1185-1194
Looker, A.C., Orwoll, E.S., Johnston, C.C., Jr., Lindsay, R.L., Wahner, H.W., Dunn, W.L., Prevalence of low femoral bone density in older U.S. adults from NHANES III (1997) J Bone Miner Res, 12 (11), pp. 1761-1768
Kanis, J.A., Johnell, O., De Laet, C., Johansson, H., Oden, A., Delmas, P., A meta-analysis of previous fracture and subsequent fracture risk (2004) Bone, 35 (2), pp. 375-382
Klotzbuecher, C.M., Ross, P.D., Landsman, P.B., Abbott, T.A., 3rd, Berger, M., Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis (2000) J Bone Miner Res, 15 (4), pp. 721-739
Johansson, H., Siggeirsdottir, K., Harvey, N.C., Oden, A., Gudnason, V., McCloskey, E., Imminent risk of fracture after fracture (2017) Osteoporos Int, 28 (3), pp. 775-780
Johansson, H., (2017), Risk of hip fracture after recent fracture – comparison of sentinel fracture sites (Reykjavik Study). ASBMR Meeting
Haentjens, P., Magaziner, J., Colon-Emeric, C.S., Vanderschueren, D., Milisen, K., Velkeniers, B., Meta-analysis: excess mortality after hip fracture among older women and men (2010) Ann Int Med, 152 (6), pp. 380-390
Johnell, O., Kanis, J.A., Oden, A., Sernbo, I., Redlund-Johnell, I., Petterson, C., Mortality after osteoporotic fractures (2004) Osteoporos Int, 15 (1), pp. 38-42
Kanis, J.A., Oden, A., Johnell, O., De Laet, C., Jonsson, B., Excess mortality after hospitalisation for vertebral fracture (2004) Osteoporos Int, 15 (2), pp. 108-112
Kanis, J.A., Oden, A., Johnell, O., De Laet, C., Jonsson, B., Oglesby, A.K., The components of excess mortality after hip fracture (2003) Bone, 32 (5), pp. 468-473
Cauley, J.A., Thompson, D.E., Ensrud, K.C., Scott, J.C., Black, D., Risk of mortality following clinical fractures (2000) Osteoporos Int, 11 (7), pp. 556-561
Kanis, J.A., Oden, A., Johnell, O., De Laet, C., Jonsson, B., Excess mortality after hospitalisation for vertebral fracture (2004) Osteoporos Int, 15 (2), pp. 108-112
Tran, T., Bliuc, D., van Geel, T., Adachi, J.D., Berger, C., van den Bergh, J., Population-wide impact of non-hip non-vertebral fractures on mortality (2017) J Bone Miner Res, 32 (9), pp. 1802-1810
Weaver, J., Sajjan, S., Lewiecki, E.M., Harris, S.T., Marvos, P., Prevalence and cost of subsequent fractures among U.S. patients with an incident fracture (2017) J Manag Care Spec Pharm, 23 (4), pp. 461-471
Hiligsmann, M., Reginster, J.Y., Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium (2011) Pharmacoeconomics, 29 (10), pp. 895-911
Silverman, S.L., Minshall, M.E., Shen, W., Harper, K.D., Xie, S., The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the multiple outcomes of raloxifene evaluation study (2001) Arthritis Rheum, 44 (11), pp. 2611-2619
Liu, H., Michaud, K., Nayak, S., Karpf, D.B., Owens, D.K., Garber, A.M., The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis (2006) Arch Intern Med, 166 (11), pp. 1209-1217
Cheng, L.I., Durden, E., Limone, B., Radbill, L., Juneau, P.L., Spangler, L., Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States (2015) J Manag Care Spec Pharm, 21 (9), pp. 824-U322
